GlassScriptPhysician profile
Moshe Lewis
NPI 1801816921
$979.30
in general payments reported to CMS, 2019-2025
14 companies · $22.75 in 2025
The $22.75 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $130 · 2021: $123 · 2022: $33.54 · 2023: $28.75 · 2025: $22.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $227.75 | 2019-2021 | |
| Amgen INC. | $127.01 | 2019 | |
| Scilex Pharmaceuticals INC. | $122.97 | 2019-2022 | |
| Indivior INC. | $109.99 | 2019-2025 | Sublocade |
| Abbott Laboratories | $83.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $72.89 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $60.16 | 2019-2021 | |
| Genentech USA, INC. | $45.89 | 2019-2020 | |
| Kaleo, INC. | $32.12 | 2019 | |
| Abbvie INC. | $28.75 | 2023 | |
| Bioventus LLC | $22.28 | 2019 | |
| Forte Bio-Pharma LLC | $19.36 | 2021 | |
| Shionogi INC | $13.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshe Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.